Tremendous advancements have been made since the first U.S. human heart transplant was performed in 1968. Today, promising new studies involving devices and procedures are giving hope to the 5.1 million advanced heart failure patients living in the U.S.
Several studies currently being conducted by physicians, researchers and scientists at the University of Michigan Frankel Cardiovascular Center are building on the success of our Heart Failure Program. These include:
- MOMENTUM III: This study compares the HeartMate III heart pump with an older version (HeartMate II) to evaluate whether a smaller pump design with new features will benefit patients with advanced stages of heart failure. The heart pump is intended as a bridge to heart transplantation or as destination therapy.
- CTSN Cell Therapy LVAD Trial II: This study will evaluate the use of stems cells that are injected into the patient’s heart at the time of receiving a Left Ventricle Assist Device (LVAD). This study will determine if stem cells improve the function of the heart.